|

Pemetrexed 500 mg/m2 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since July 2026

Also known as: Alimta®

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Yang Hong1
  • Inhibrx Biosciences, Inc1

Indications

  • Lung Cancer2
  • Cancer2
  • Stage IIIC Non-Small Cell Lung Cancer1
  • Stage IIIB Non-small Cell Lung Cancer1
  • Resectable Non-Small-Cell Lung Cancer1

Other1 trial

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
Phase 2

Duarte, California1 trial

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

City of Hope

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.